<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02349477</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00032587</org_study_id>
    <nct_id>NCT02349477</nct_id>
  </id_info>
  <brief_title>Gabapentin for Alcohol Relapse Prevention</brief_title>
  <official_title>Gabapentin for Relapse Prevention: Alcohol Withdrawal Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This treatment study is a 16-weeks outpatient clinical trial where subjects with alcohol
      dependence will get medication, which might help them to reduce or stop their drinking, or a
      placebo ( placebo is a capsule that looks the same as the investigational drug, but has no
      real medication. It is a &quot;sugar pill&quot;).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This treatment study is a 16-weeks outpatient clinical trial where subjects will get
      medication, which might help them to reduce or stop their drinking or a placebo ( placebo is
      a capsule that looks the same as the investigational drug, but has no real medication. It is
      a &quot;sugar pill&quot;). This study will recruit and randomize subjects who have expressed an
      interest in receiving treatment for alcohol dependence. Upon enrollment into this study there
      will be 11 outpatient visits. Each visit will last about 1-1.5 hours.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">August 27, 2018</completion_date>
  <primary_completion_date type="Actual">August 27, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Subjects With no Heavy Drinking Days (PSNHDD)</measure>
    <time_frame>4 months</time_frame>
    <description>The primary dependent variable will be the percent of subjects with no heavy drinking days (4 or more standard drinks for women and 5 or more standard drinks for men). Participants will report their daily alcohol use with using a daily calendar. No heavy drinking days is corrected for %dCDT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With no Drinking Days (PSNDD)</measure>
    <time_frame>4 months</time_frame>
    <description>The secondary dependent variable will be percent of subjects with no drinking days (total abstinence). Participants will report their daily alcohol use with using a daily calendar. Abstinence is corrected for %dCDT.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With No Drinking Days by AWS Score and Medication</measure>
    <time_frame>4 months</time_frame>
    <description>This analysis examines the interaction of medication group with a median split of the baseline Alcohol Withdrawal Scale (AWS) scores on the primary outcome variable (no heavy drinking days, corrected for %dCDT). Participants will report their daily alcohol use with using a daily calendar. AWS ranges from 0 to 44 where higher values correspond with more serious withdrawal (worse outcome).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <condition>Alcohol Withdrawal</condition>
  <arm_group>
    <arm_group_label>Gabapentin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gabapentin up to 1200 mg per day in 3 divided doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gabapentin</intervention_name>
    <description>gaba potentiating medication</description>
    <arm_group_label>Gabapentin</arm_group_label>
    <other_name>neurontin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>a pill that looks exactly like the active medication but does not contain medication</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meets criteria for alcohol use disorder based on DSM-5 criteria

          2. Meets criteria for history of alcohol withdrawal based on DSM-5 criteria

          3. Able to maintain abstinence for a minimum of 3 days prior to randomization as verified
             by self report, urine ETG, and breathalyzer.

        Exclusion Criteria:

          1. Significant psychiatric or medical illness

          2. No other substance abuse

          3. Taking other medications known to treat alcohol use disorder

          4. Unstable living arrangements

          5. Significant legal problems pending
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond F Anton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 15, 2015</study_first_submitted>
  <study_first_submitted_qc>January 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2015</study_first_posted>
  <results_first_submitted>August 29, 2019</results_first_submitted>
  <results_first_submitted_qc>October 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 4, 2019</results_first_posted>
  <last_update_submitted>October 15, 2019</last_update_submitted>
  <last_update_submitted_qc>October 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gabapentin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 16, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02349477/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The discrepancy of 6 participants is due to those subjects either violating protocol or not having evaluable data.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Gabapentin</title>
          <description>Gabapentin up to 1200 mg per day in 3 divided doses
Gabapentin: gaba potentiating medication</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>matching placebo
Placebo: a pill that looks exactly like the active medication but does not contain medication</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Gabapentin</title>
          <description>Gabapentin up to 1200 mg per day in 3 divided doses
Gabapentin: gaba potentiating medication</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>matching placebo
Placebo: a pill that looks exactly like the active medication but does not contain medication</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.3" spread="10.4"/>
                    <measurement group_id="B2" value="48.9" spread="9.9"/>
                    <measurement group_id="B3" value="49.6" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>% Heavy Drinking Days</title>
          <description>% heavy drinking days out of the 90 days reported via timeline followback. A heavy drinking day is defined as 4 or more drinks for females and 5 or more drinks for males in one day.</description>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.9" spread="23"/>
                    <measurement group_id="B2" value="82.5" spread="21.6"/>
                    <measurement group_id="B3" value="82.7" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Subjects With no Heavy Drinking Days (PSNHDD)</title>
        <description>The primary dependent variable will be the percent of subjects with no heavy drinking days (4 or more standard drinks for women and 5 or more standard drinks for men). Participants will report their daily alcohol use with using a daily calendar. No heavy drinking days is corrected for %dCDT.</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Gabapentin up to 1200 mg per day in 3 divided doses
Gabapentin: gaba potentiating medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo
Placebo: a pill that looks exactly like the active medication but does not contain medication</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With no Heavy Drinking Days (PSNHDD)</title>
          <description>The primary dependent variable will be the percent of subjects with no heavy drinking days (4 or more standard drinks for women and 5 or more standard drinks for men). Participants will report their daily alcohol use with using a daily calendar. No heavy drinking days is corrected for %dCDT.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis compares between Gabapentin and Placebo, the number of individuals who reported no heavy drinking days throughout the entire trial, corrected for %dCDT.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.028</p_value>
            <method>Regression, Logistic</method>
            <method_desc>This is the p-value output from the logistic regression model where medication group predicted the discrete variable for no heavy drinking days.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.9</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects With no Drinking Days (PSNDD)</title>
        <description>The secondary dependent variable will be percent of subjects with no drinking days (total abstinence). Participants will report their daily alcohol use with using a daily calendar. Abstinence is corrected for %dCDT.</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gabapentin</title>
            <description>Gabapentin up to 1200 mg per day in 3 divided doses
Gabapentin: gaba potentiating medication</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>matching placebo
Placebo: a pill that looks exactly like the active medication but does not contain medication</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With no Drinking Days (PSNDD)</title>
          <description>The secondary dependent variable will be percent of subjects with no drinking days (total abstinence). Participants will report their daily alcohol use with using a daily calendar. Abstinence is corrected for %dCDT.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This analysis compares between Gabapentin and Placebo, the number of individuals who reported no drinking days (abstinence) throughout the entire trial, corrected for %dCDT.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.053</p_value>
            <method>Regression, Logistic</method>
            <method_desc>This is the p-value output from the logistic regression model where medication group predicted the discrete variable for abstinence.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.9</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With No Drinking Days by AWS Score and Medication</title>
        <description>This analysis examines the interaction of medication group with a median split of the baseline Alcohol Withdrawal Scale (AWS) scores on the primary outcome variable (no heavy drinking days, corrected for %dCDT). Participants will report their daily alcohol use with using a daily calendar. AWS ranges from 0 to 44 where higher values correspond with more serious withdrawal (worse outcome).</description>
        <time_frame>4 months</time_frame>
        <population>The data for this analysis were split into two subgroups, based on the median split of AWS.</population>
        <group_list>
          <group group_id="O1">
            <title>Low AWS/Gabapentin</title>
            <description>Low on AWS median split variable, Gabapentin</description>
          </group>
          <group group_id="O2">
            <title>Low AWS/Placebo</title>
            <description>Low on AWS median split variable, Placebo</description>
          </group>
          <group group_id="O3">
            <title>High AWS/Gabapentin</title>
            <description>High on AWS median split variable, Gabapentin</description>
          </group>
          <group group_id="O4">
            <title>High AWS/Placebo</title>
            <description>High on AWS median split variable, Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With No Drinking Days by AWS Score and Medication</title>
          <description>This analysis examines the interaction of medication group with a median split of the baseline Alcohol Withdrawal Scale (AWS) scores on the primary outcome variable (no heavy drinking days, corrected for %dCDT). Participants will report their daily alcohol use with using a daily calendar. AWS ranges from 0 to 44 where higher values correspond with more serious withdrawal (worse outcome).</description>
          <population>The data for this analysis were split into two subgroups, based on the median split of AWS.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>For the High AWS group, a chi squared analysis compares the number of individuals with no heavy drinking days between medication groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.001</p_value>
            <method>Chi-squared</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For the Low AWS group, a chi squared analysis compares the number of individuals with no heavy drinking days between medication groups.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.67</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Entire study - 16 weeks.</time_frame>
      <desc>Participants were evaluated via the SAFTEE interview 9 times throughout the 16 week period.
We report the whole SAFTEE.</desc>
      <group_list>
        <group group_id="E1">
          <title>Gabapentin</title>
          <description>Gabapentin up to 1200 mg per day in 3 divided doses
Gabapentin: gaba potentiating medication</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>matching placebo
Placebo: a pill that looks exactly like the active medication but does not contain medication</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="44"/>
                <counts group_id="E2" events="16" subjects_affected="11" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="62" subjects_affected="23" subjects_at_risk="44"/>
                <counts group_id="E2" events="42" subjects_affected="23" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="26" subjects_affected="14" subjects_at_risk="44"/>
                <counts group_id="E2" events="33" subjects_affected="18" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="44"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="18" subjects_affected="12" subjects_at_risk="44"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Decreased Libido</sub_title>
                <counts group_id="E1" events="24" subjects_affected="12" subjects_at_risk="44"/>
                <counts group_id="E2" events="11" subjects_affected="5" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="122" subjects_affected="30" subjects_at_risk="44"/>
                <counts group_id="E2" events="108" subjects_affected="30" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Increased Appetite</sub_title>
                <counts group_id="E1" events="52" subjects_affected="23" subjects_at_risk="44"/>
                <counts group_id="E2" events="32" subjects_affected="18" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Increased Libido</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="92" subjects_affected="31" subjects_at_risk="44"/>
                <counts group_id="E2" events="130" subjects_affected="33" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="44"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="60" subjects_affected="25" subjects_at_risk="44"/>
                <counts group_id="E2" events="27" subjects_affected="15" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="129" subjects_affected="32" subjects_at_risk="44"/>
                <counts group_id="E2" events="89" subjects_affected="34" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="80" subjects_affected="24" subjects_at_risk="44"/>
                <counts group_id="E2" events="60" subjects_affected="22" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Nervousness/Anxiety</sub_title>
                <counts group_id="E1" events="172" subjects_affected="35" subjects_at_risk="44"/>
                <counts group_id="E2" events="127" subjects_affected="32" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="12" subjects_affected="4" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="26" subjects_affected="10" subjects_at_risk="44"/>
                <counts group_id="E2" events="21" subjects_affected="9" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="17" subjects_affected="7" subjects_at_risk="44"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michaela Hoffman</name_or_title>
      <organization>Medical University of South Carolina</organization>
      <phone>8437927758</phone>
      <email>HoffmaMi@musc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

